Guus F Rimmelzwaan


Affiliation: Erasmus MC
Country: The Netherlands


  1. Altenburg A, Kreijtz J, de Vries R, Song F, Fux R, Rimmelzwaan G, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014;6:2735-61 pubmed publisher
    ..In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses. ..
  2. Hillaire M, van Eijk M, Vogelzang van Trierum S, Nieuwkoop N, van Riel D, Fouchier R, et al. Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro. Virus Res. 2015;195:43-6 pubmed publisher
    ..Here we show that RpSP-D neutralizes influenza B viruses efficiently and inhibited the binding of these viruses to epithelial cells of the human trachea. ..
  3. van de Sandt C, Kreijtz J, Geelhoed Mieras M, Vogelzang van Trierum S, Nieuwkoop N, van de Vijver D, et al. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine. 2014;32:5614-23 pubmed publisher
  4. Wiersma L, Vogelzang van Trierum S, Kreijtz J, van Amerongen G, van Run P, Ladwig M, et al. Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus. Vaccine. 2015;33:6977-82 pubmed publisher
    ..Thus infection with H1N1pdm09 virus induced partially protective heterosubtypic immunity to H7N9 virus in (isogenic) guinea pigs that could not be attributed to cross-reactive virus neutralizing antibodies. ..
  5. Altenburg A, Rimmelzwaan G, de Vries R. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine. 2015;33:500-6 pubmed publisher
    ..Furthermore, we discuss vector-based vaccination strategies that aim at the induction of a cross-reactive virus-specific T cell response. ..
  6. Rimmelzwaan G, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines. 2009;8:447-54 pubmed publisher
    ..Specifically, we will focus on the preclinical evaluation of recombinant MVA vector as pandemic influenza A/H5N1 vaccine candidates and discuss the possible future approaches for the use of these novel MVA-based vaccines. ..
  7. van de Sandt C, Kreijtz J, Geelhoed Mieras M, Nieuwkoop N, Spronken M, van de Vijver D, et al. Differential Recognition of Influenza A Viruses by M158-66 Epitope-Specific CD8+ T Cells Is Determined by Extraepitopic Amino Acid Residues. J Virol. 2016;90:1009-22 pubmed publisher
    ..These results provide novel insights into the epidemiology of influenza A viruses and their pathogenicity and may aid rational design of vaccines that aim at the induction of CTL responses. ..
  8. Wiersma L, Rimmelzwaan G, de Vries R. Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel). 2015;3:239-62 pubmed publisher
  9. Wiersma L, Kreijtz J, Vogelzang van Trierum S, van Amerongen G, van Run P, Ladwig M, et al. Virus replication kinetics and pathogenesis of infection with H7N9 influenza virus in isogenic guinea pigs upon intratracheal inoculation. Vaccine. 2015;33:6983-7 pubmed publisher
    ..This study indicates that isogenic guinea pigs are a promising model to further study immunity to and transmission of H7N9 influenza virus. ..

More Information


  1. Wiersma L, Vogelzang van Trierum S, van Amerongen G, van Run P, Nieuwkoop N, Ladwig M, et al. Pathogenesis of infection with 2009 pandemic H1N1 influenza virus in isogenic guinea pigs after intranasal or intratracheal inoculation. Am J Pathol. 2015;185:643-50 pubmed publisher
    ..In summary, isogenic guinea pigs show promise as a model to investigate the role of humoral and cell-mediated immunities to influenza and their effect on virus transmission. ..
  2. Jong W, Daleke Schermerhorn M, Vikström D, ten Hagen Jongman C, de Punder K, van der Wel N, et al. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Fact. 2014;13:162 pubmed publisher
    ..The successful efficient cell surface display of multiple antigens from various pathogenic organisms highlights the potential of Hbp as a universal platform for the development of multivalent recombinant bacterial vector vaccines. ..
  3. Rimmelzwaan G, Kreijtz J, Bodewes R, Fouchier R, Osterhaus A. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine. 2009;27:6363-5 pubmed publisher
    ..A mutational analysis of this epitope indicated that it is under functional constraints. Also in influenza A viruses of other subtypes, including H5N1, the M1(58-66) is highly conserved. ..
  4. Altenburg A, van de Sandt C, van Trierum S, De Gruyter H, van Run P, Fouchier R, et al. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. J Virol. 2016;90:10209-10219 pubmed publisher
    ..Although we were unable to increase the NP-specific immune response in the mouse strain used, this approach may have benefits for vaccine development using less-immunogenic proteins. ..
  5. de Vries R, Altenburg A, Rimmelzwaan G. Universal influenza vaccines: a realistic option?. Clin Microbiol Infect. 2016;22 Suppl 5:S120-S124 pubmed publisher
    ..We review options for the development of universal flu vaccines and discuss progress that has been made recently. ..
  6. Rimmelzwaan G, Verburgh R, Nieuwkoop N, Bestebroer T, Fouchier R, Osterhaus A. Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies. Vaccine. 2011;29:3424-30 pubmed publisher
  7. request reprint
    Rimmelzwaan G, Boon A, Geelhoed Mieras M, Voeten J, Fouchier R, Osterhaus A. Human airway epithelial cells present antigen to influenza virus-specific CD8+ CTL inefficiently after incubation with viral protein together with ISCOMATRIX. Vaccine. 2004;22:2769-75 pubmed
  8. de Vries R, Nieuwkoop N, Pronk M, de Bruin E, Leroux Roels G, Huijskens E, et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine. 2017;35:238-247 pubmed publisher
    ..This assay will facilitate the assessment of ADCC mediating serum antibodies after (universal) influenza vaccination or infection and may define ADCC activity as a correlate of (cross-) protection in the future. ..
  9. Wumkes M, van der Velden A, de Bruin E, Meerveld Eggink A, Koopmans M, Rimmelzwaan G, et al. Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy. Vaccine. 2017;35:1299-1305 pubmed publisher
    ..Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer. ..
  10. Ortiz J, Hickling J, Jones R, Donabedian A, Engelhardt O, Katz J, et al. Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. Vaccine. 2018;36:932-938 pubmed publisher
    ..This report highlights the major discussions of the meeting. ..